The condom, which is currently known as CSD500, has been developed by Futura.
“It’s essentially Viagra in a condom,” Daniel Mahony, a London hedge-fund manager who owns shares of Futura, told Business Week.
"CSD500, our Condom Safety Device is a condom developed for use by healthy men," reads the information on the Futura Medical
website. "The product incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom. The gel is to be licensed under the trademarked brand name of Zanifil®."
Zanifil, which is based on nitroglycerin, relaxes the muscles in the vessel walls, widening them and increasing blood flow.
The company reported that, in a double blind study, a significant proportion of those who expressed a preference reported improvements in the firmness of the man's erection during intercourse when using CSD500, compared against a standard condom.
"Furthermore, of those who expressed a preference, a significant proportion of both men and women also felt that CSD500 increased the penis size and a significant proportion of women reported a longer lasting sexual experience with CSD500," it added.
The Huffington Post
reported that the condom was given a CE mark in August, meaning it can be sold in Europe over the counter.
The company has a global distribution agreement with the Reckitt Benckiser Group, makers of Durex, which is expected to launch the product soon.
Nerve reported that, according to Futura's CEO, James Barder, the main reason the product isn't available yet is due to a sensitivity issue.
"If the packaging says it will give you a bigger penis, and a woman gives it to a man, it might cause a reaction, like, 'What, you're saying my penis is small?' This area does have sensitivities. Positioning is critical," Nerve
quoted him as saying.
Futura is also developing a topical spray that helps delay ejaculation.